| Literature DB >> 27357502 |
Peter Damborg1, Arshnee Moodley2, Bent Aalbæk2, Gianpiero Ventrella3, Teresa Pires Dos Santos2, Luca Guardabassi2,4.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus pseudintermedius (MRSP) has emerged globally in companion animals in the last decade. In Europe, the multidrug-resistant sequence type (ST)71 is widespread, but recently other clones have appeared. The objective of this study was to examine genotypic diversity and antimicrobial resistance of clinical MRSP isolates obtained from dogs, including dogs sampled on multiple occasions, in Denmark over a six-year period. For that purpose a total of 46 clinical MRSP isolates obtained from 36 dogs between 2009 and 2014 were subjected to antimicrobial susceptibility testing, multilocus-sequence typing (MLST) and SCCmec typing.Entities:
Keywords: Antibiotic resistance; Dog; MRSP; Multilocus sequence typing; ST258; ST71
Mesh:
Substances:
Year: 2016 PMID: 27357502 PMCID: PMC4928297 DOI: 10.1186/s12917-016-0756-y
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Characteristics of the 46 MRSP isolates included in the study
| Clonal Com-plex | MLST type | No. of isolates | No. of dogs | SCC | No. (type) of antibiotics susceptible toa |
|---|---|---|---|---|---|
| CC45 | ST45 | 3 | 3 | NTb | 2-3 ( |
| ST288c | 1 | 1 | V | 3 (AMI, CHL, RIF) | |
| CC68 | ST271c | 1 | 1 | V | 4 (AMI, CHL, GEN, RIF) |
| CC71 | ST71 | 13 | 13 | II-III ( | 2–5 ( |
| ST270c | 1 | 1 | II–III | 3 (CHL, RIF, SXT) | |
| ST272d | 1 | 1 | II–III | 2 (CHL, RIF) | |
| CC258 | ST118d | 1 | 1 | IV | 7 (AMI, CHL, ENR, GEN, MAR, RIF, SXT) |
| ST258 | 7 | 2 | IV | 4–6 (AMI, | |
| ST261c | 1 | 1 | IV | 5 (AMI, CHL, GEN, MAR, RIF) | |
| ST265d | 1 | 1 | IV | 4 (CHL, ENR, MAR, RIF) | |
| ST267d | 1 | 1 | IV | 6 (AMI, CHL, ENR, GEN, MAR, RIF) | |
| ST273c | 2 | 1 | IV | 6 (AMI, CHL, ENR, GEN, MAR, RIF) | |
| ST277c | 1 | 1 | IV | 6 (AMI, ENR, GEN, MAR, RIF) | |
| ST290d | 2 | 2 | IV, NT | 6 (AMI, CHL, ENR, GEN, MAR, RIF) | |
| ST301d | 1 | 1 | IV | 4 (CLI, ERY, MAR, RIF) | |
| ST414d | 1 | 1 | IV | 5 (AMI, CHL, GEN, RIF, SXT) | |
| ST430d | 1 | 1 | IV | 7 (AMI, CHL, ENR, GEN, MAR, RIF, SXT) | |
| NAe | ST431 | 1 | 1 | V | 7 (AMI, CHL, CLI, DOX, ERY, GEN, RIF) |
| ST268 | 1 | 1 | IV | 7 (AMI, CHL, ENR, GEN, MAR, RIF, SXT) | |
| ST269 | 2 | 2 | IV | 6–7 (AMI, CHL, ENR, | |
| ST284 | 1 | 1 | V | 3 (AMI, RIF, SXT) | |
| ST286 | 1 | 1 | IV | 6 (AMI, CHL, ENR, GEN, MAR, RIF) | |
| ST295 | 1 | 1 | NT | 7 (AMI, DOX, ENR, GEN, MAR, RIF, SXT) |
AMI amikacin, CHL chloramphenicol, CLI clindamycin, DOX doxycycline, ENR enrofloxacin, ERY erythromycin, GEN gentamicin, MAR marbofloxacin, RIF rifampicin, SXT sulphamethoxazole and trimethoprim
aOut of the 22 antibiotics in the COMPAN1F broth microdilution panel. Underlined antibiotics are those for which some isolates within an ST were susceptible and others resistant
bNT, not typeable with the method of Kondo et al. [11]
cSLV of the founder of the clonal complex
dDLV of the founder of the clonal complex
eNA, not applicable as the STs are singletons
MRSP clones over time in dogs that were MRSP positive on at least two sampling occasions
| Dog ID | Date of isolation (month/year) | MLST type | Relatedness of clones |
|---|---|---|---|
| A | 12/09 | ST268 | 6 of 7 alleles in common (SLVs) |
| 08/10 | ST269 | ||
| B | 12/12 | ST45 | 1 of 7 alleles in common |
| 01/13 | ST71 | ||
| C | 07/12 | ST258 | – |
| 10/12 | ST258 | ||
| D | 10/12 | ST71 | 2 of 7 alleles in common |
| 11/12 | ST295 | ||
| E | 01/12 | ST258 | 6 of 7 alleles in common (SLVs) |
| 03/12 | ST273 | ||
| 06/12 | ST273 | ||
| 07/12 | ST258 | ||
| 11/12 | ST258 | ||
| 12/12 | ST258 | ||
| 02/13 | ST258 |